CORRESPONDENCE



Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients

To the editor.

We would like to share ideas on the article "Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients."[1] Most liver transplant recipients generate an immune response to the Moderna severe acute respiratory syndrome coronavirus 2 messenger RNA-based vaccine, and a limited serologic response is predicted by an immunosuppressive regimen that includes mycophenolate.[1] We agree that the immunologic response to the corona virus disease 2019 (COVID-19) vaccine may differ from that of a healthy person. Immunosuppressive medication may have an impact on vaccination immunologic response. However, we should be aware of the potential impact of asymptomatic COVID-19. Asymptomatic infection is not rare, [2] and it must be ruled out in any investigation of the novel COVID-19 vaccine's efficacy. The immunologic response reported in the current investigation by Cuadrado et al.^[1] could be influenced by asymptomatic infection before and after immunization.

CONFLICT OF INTEREST Nothing to report.

Rujittika Mungmunpuntipantip¹ Viroi Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand ²Dr DY Patil University, Pune, India

Correspondence

Rujittika Mungmunpuntipantip, Private Academic Consultant, Bangkok, Thailand. Email: rujittika@gmail.com

ORCID

Rujittika Mungmunpuntipantip https://orcid. org/0000-0003-0078-7897

REFERENCES

- 1. Cuadrado A, Del Barrio M, Fortea JI, Amigo L, San Segundo D, Rodriguez-Cundin MP, et al. Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients. Hepatol Commun. 2022. https://doi.org/10.1002/hep4.1937
- 2. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020;53:70.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.